Atomoxetine facilitates attentional set shifting in adolescent rats  by Cain, Rachel E. et al.
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Adolescent  rats  show  immaturities  in  executive  function  and  are  less  able  than  adult  rats  to
learn  reinforcement  reversals  and  shift  attentional  set.  These  two forms  of  executive  func-
tion rely  on  the functional  integrity  of the  orbitofrontal  and  prelimbic  cortices  respectively.
Drugs  used  to treat  attention  deﬁcit  disorder,  such  as  atomoxetine,  that  increase  cortical  cat-
echolamine  levels  improve  executive  functions  in humans,  non-human  primates  and  adult
rats with  prefrontal  lesions.  Cortical  noradrenergic  systems  are  some  of  the  last  to  mature  in
primates  and  rats. Moreover,  norepinephrine  transporters  (NET)  are  higher  in  juvenile  rats
than  adults.  The  underdeveloped  cortical  noradrenergic  system  and  higher  number  of  NET
are hypothesized  to underlie  the  immaturities  in  executive  function  found  in  adolescents.
We  assessed  executive  function  in  male  Long-Evans  rats  using  an  intra-dimensional/extra-
dimensional  set  shifting  task.  We  administered  the  NET  blocker,  atomoxetine  (0.0,  0.1,
0.9 mg/kg/ml;  i.p.),  prior  to the  test  of attentional  set  shift  and  a reinforcement  reversal.
The lowest  dose  of  drug  facilitated  attentional  set  shifting  but  had  no  effect  on  reversal
learning.  These  data  demonstrate  that  NET  blockade  allows  adolescent  rats  to  more  easily
l  set shperform attentiona
Though the neurochemical and neuroanatomical basis
f attentional function in adults has been elucidated by
tudies in humans (Chamberlain et al., 2007; Spencer et al.,
998) and through translational research using animals
Arnsten, 1998; Aston-Jones et al., 2000; Baxter et al., 1995;
irrell and Brown, 2000; Dalley et al., 2004; McGaughy
t al., 1996; Sarter et al., 2005), the ontogeny of attention
emains poorly understood. Much of the research on exec-
tive functions and adolescence has focused on changes
n the dopaminergic systems (Black et al., 2006; Dow-
dwards et al., 2008; Greydanus et al., 2007; Kuczenski
nd Segal, 2002; Laviola et al., 1999; Loveland et al.,
008; Parker et al., 2007; Schulz et al., 2005). These sys-
ems have been implicated in response inhibition (Barkley,
997; Dalley et al., 2004; Robbins, 2000) reward process-
ng (Adriani et al., 2006; Brenhouse and Andersen, 2008;
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Brenhouse et al., 2008; Laboni et al., 1995) and may  be
dysfunctional in adolescents with attention deﬁcit hyper-
activity disorder (ADHD) (Castellanos and Tannock, 2002;
Greydanus et al., 2007; Kieling et al., 2008; Sagvolden
and Sergeant, 1998; Shafritz et al., 2004; Solanto, 1984;
Sonuga-Barke et al., 2008; Viggiano et al., 2004) Tourette’s
syndrome (Andersen, 2008) and those individuals suscep-
tible to substance abuse disorders (Berke and Hyman, 2000;
Brenhouse et al., 2008; Burns et al., 1994; Robbins and
Everitt, 1999). These data have provided important insights
into one aspect of executive function that may  develop
during adolescence However, other aspects of executive
function such as the ability to rapidly and appropriately
re-direct attention has been shown to depend not on
prefrontal dopamine, but on the functional integrity of
prefrontal norepinephrine (NE: Lapiz and Morilak, 2006;
McGaughy et al., 2008; Milstein et al., 2007; Newman et al.,
2008; Tait et al., 2007).
Noradrenergic projections to frontal cortex have been
hypothesized to be mature by post-natal day (PND)
25(Coyle and Axelrod, 1972; Harden et al., 1977; Levitt
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and Moore, 1979; Morrison et al., 1979; Wendlandt et al.,
1977). Unlike ﬁber density which is mature by PND 25,
norepinephrine transporter (NET) density dramatically
decreases between PND 25 and PND 90 (Moll et al., 2000;
Sanders et al., 2005). Recent data suggests that a polymor-
phism in the NET gene is associated with a higher incidence
of attention deﬁcit disorder in both Korean and U.S. pop-
ulations (Joung et al., 2009; Xu et al., 2008). Drugs such as
methylphenidate and atomoxetine that block NET, increase
levels of prefrontal norepinephrine, (Bymaster et al., 2002;
Christman et al., 2004; Tzavara et al., 2007) are used to treat
ADHD (Biederman et al., 2002; Chamberlain et al., 2007;
Christman et al., 2004; Kratochvil et al., 2003; Kratochvil
et al., 2006; Newcorn et al., 2008; Newman et al., 2008)
or improve cognition in normal subjects (Berridge and
Waterhouse, 2003; Chamberlain et al., 2008; Mehta et al.,
2000).
We hypothesize that the density of NET in prefrontal
cortex is critical to executive function. Speciﬁcally, the
higher density of NET in young rats is (Moll et al., 2000)
hypothesized to decrease the amount of time NE is avail-
able in the synaptic cleft preventing shifts of attention
(Aston-Jones et al., 2000, 2001; Aston-Jones and Cohen,
2005; Bouret and Sara, 2004, 2005). Recent data from our
lab have shown that adolescents tested at PND 40 and
43 were more cognitively rigid than adults (Newman and
McGaughy, 2011). The behavior exhibited by normal ado-
lescents is similar to that of adult rats following a loss of
noradrenergic afferents to the prelimbic cortex (Newman
et al., 2008; Tait et al., 2007). Previous work has shown
that the administration of atomoxetine restores normal
attentional set shifting abilities in rats after noradrenergic
deafferentation (Newman et al., 2008), improves behav-
ioral ﬂexibility in rats and monkeys (Seu et al., 2008), and
response inhibition in patients with ADHD (Chamberlain
et al., 2007, 2008; Christman et al., 2004; Kratochvil et al.,
2003). In the present study, we test the hypothesis that the
higher density of NET in the prefrontal cortex of adolescent
rats produces attentional rigidity that may  remediated by
the systemic administration of the selective NET blocker
atomoxetine. Executive abilities were assessed in a test of
cognitive ﬂexibility that allowed the assessment of com-
plex, conditional discriminations, reversal learning, as well
as the formation and shifting of an attentional set (Birrell
and Brown, 2000; Lapiz-Bluhm et al., 2009; Lapiz et al.,
2007; McAlonan and Brown, 2003; McGaughy et al., 2008).
We hypothesized that the administration of a low dose
of atomoxetine that increases prefrontal NE selectively
would be more effective at producing ﬂexible cognitive
performance than a higher dose of the drug that may
increase levels of norepinephrine beyond the range optimal
for behavioral ﬂexibility (Aston-Jones and Cohen, 2005;
Arnsten, 2006a,b; Bouret and Sara, 2005).
1. Methods
1.1. SubjectsTwelve male, Long-Evans adolescent rats (Charles River,
Wilmington, MA)  were used in this study. Rats were PND 39
and had achieved pre-putial separation prior to the onset Neuroscience 1 (2011) 552– 559 553
of behavioral training. Each rat was  housed individually
and maintained on a 12 h light/dark cycle with lights on at
7:00am. Testing occurred between 9am and 1pm daily. Rats
were moderately food restricted (12–15 g/day) and given
water ad libitum. All procedures described were approved
by the University of New Hampshire Institutional Animal
Care and Use Committee in accordance the Guide for the
Care and Use of Laboratory Animal.
1.2. Materials
Animals were tested in a plastic testing box
(91.44 cm × 45.72 cm × 25.40 cm,  L × W × H; Sterilite,
Townsend, MA)  and trained to dig in terra cotta pots with
a height of 6.1 cm and diameter of 6.1 cm that varied in
three dimensions: texture, digging media, and odor. A
removable divider was placed in the plastic testing box to
control access to stimuli.
1.3. Training to dig
Each rat was  trained to dig for a food reward (Research
Diets, New Brunswick, NJ; 45 mg  pellet) before starting
testing. An unscented terra cotta pot was ﬁlled with pine
chip bedding and placed in one end of the testing box and
separated from the rat by a divider. A reinforcer was placed
on top of the bedding and the rat was given a 90 s lim-
ited hold. A stopwatch was started when the divider was
removed. The response latency was recorded for each trial
and deﬁned as the length of time between the removal of
the divider and displacement of the digging media by the
rat using either its forepaw or nose. Subjects were required
to retrieve 5 reinforcers from atop the digging media, then
shaped to retrieve fully buried reinforcers until they suc-
cessfully retrieved 10 fully buried reinforcers.
1.4. Exemplar training
The methods described in the present study are similar
to those previously used (Birrell and Brown, 2000; Newman
et al., 2008; Newman and McGaughy, 2011). Rats were
trained to perform three separate simple, conditional dis-
criminations using sets of exemplar pots, i.e. one set in each
of the dimensions the rat would be required to attend to
during the subsequent attentional set shifting task (ASST).
The pots were wrapped in fabric to give different textures
(fake fur vs. reverse of fake fur), ﬁlled with different digging
media (white vs. green shredded paper), or scented with
different odors (cherry vs. pine). A pair of pots was placed in
the box behind a divider to prevent the rat’s access to test-
ing stimuli prior to the onset of a trial. The experimenter
removed the divider and started the timer. A response was
deﬁned as displacement of digging media by either the
forepaw or nose of a rat. After a response was made, the
timer was stopped then the response latency and accuracy
were recorded. The ﬁrst four trials of every discrimination
were designated discovery trials with a limited hold of 90 s.
If they responded incorrectly the latency was  recorded,
the trial was scored as a miss, but they were allowed to
explore the correct pot to retrieve the reinforcement. On
trials subsequent to the discovery trials, the limited hold
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Table 1
An example of a testing sequence is given below with reinforced stimuli shown in bold. In this example, the subject was ﬁrst reinforced for attending to
an  odor stimulus in the SD and maintaining attention to this same exemplar when distracting attributes were introduced in CD1. During reversal trials,
the  modality reinforced was the same as before but the alternate exemplar in a stimulus pair predicted reinforcement, e.g. patchouli. The formation of
attentional set was assessed during ID1 where subjects were presented with a novel set of stimuli and reinforced for maintaining attentional focus to the
dimension that previously predicting reinforcement, e.g. odor. Another reinforcement reversal followed this test and preceded the test of attentional set
shifting (ED1). A novel set of stimuli were introduced and subjects had to learn that a different stimulus dimension predicted reinforcement. At the same
time,  subjects had to inhibit responding to the stimulus dimension that had been paired with reinforcement in the tests of SD-IDR1.
Task Testing pair 1 Testing pair 2 Not relevant
attribute
SD Cinnamon vs. patchouli Cinnamon vs. patchouli
CD1 Cinnamon/light shapes vs. patchouli/dark
shapes
Cinnamon/dark shapes vs. patchouli/light
shapes
Fake fur
CDR1 Patchouli/light shapes vs. cinnamon/dark
shapes
Patchouli/dark shapes vs. cinnamon/light
shapes
Fake fur
ID1 Lilac/gold buttons vs. rose/black buttons Lilac/black buttons vs. rose/gold buttons Ribbed side
corduroy
IDR1  Rose/gold buttons vs. lilac/black buttons Rose/black buttons vs. lilac/gold buttons Ribbed side
corduroy
ED1  Metal beads/gardenia vs. plastic beads/jasmine Metal beads/jasmine vs. plastic beads/gardenia Terrycloth
EDR1  Plastic beads/gardenia vs. metal Plastic beads/jasmine vs. metal
bea
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LI  1 Plastic beads/terrycloth vs. metal
beads/reverse terrycloth
as reduced to 60 s and the animal was no longer allowed
o explore the correct pot if an incorrect choice was  made.
ecause a criterion of six correct consecutive trials could
e achieved by chance alone in 64 trials and pilot studies
howed that adolescent rats required more than 64 trials
o master a particular subtest, a more stringent criterion of
even consecutive correct trials was applied to all stages
f shaping and testing. Previous work has shown that this
ore stringent criterion when applied to training adult rats
oes not alter task acquisition (Newman and McGaughy,
011). These exemplars were not used again.
.5. Attentional set shifting task
.5.1. Simple discrimination
The ﬁrst discrimination in the attentional set shifting
ask was a simple discrimination (SD). As in the exemplar
esting, the pots differed on one dimension (texture, dig-
ing medium, or odor). The animal was again given four
iscovery trials in which they were permitted to dig in
oth pots, and again only one pot was baited (e.g. cinnamon
cented pot). Once a rat reached criterion performance, it
egan training in the compound discrimination.
.5.2. Compound discrimination (CD1)
At this stage, two additional dimensions were intro-
uced, e.g. texture and digging media, but the rat was
till rewarded for attending to the previously reinforced
imension (e.g. cinnamon). One of these two  irrelevant
imensions varies across a stimulus pairwhile the other
s held constant. This additional attribute allowed a test
f learned irrelevance after completion of the ﬁrst ASST.
he reinforced, non-reinforced and invariant dimensions
ere counterbalanced across subjects with one example
f a testing schedule provided in Table 1.ds/gardenia
tic beads/reverse terrycloth vs. metal
ds/terrycloth
Gardenia
1.5.3. CDR1
After completion of CD1, the reinforcement contingen-
cies within a modality were reversed (e.g. patchouli, not
cinnamon, scented pot was rewarded, CDR1).
1.5.4. Intra-dimensional shift (ID1)/IDR1
Upon successful completion of the CDR 1, a new set
of stimuli (new odors, digging media, textures) was intro-
duced. As before, the animal was  reinforced for attending
to the same dimension, e.g. odor. This discrimination was
known as the intra-dimensional shift (ID1). Learning at this
stage should have been facilitated by the animal maintain-
ing attentional focus to the previously reinforced stimulus
dimension so that fewer trials should be required to reach
criterion performance on ID1 than CD1. After the success-
ful completion of the ID1, another reinforcement reversal
was  performed (IDR1; e.g. a rat was  reinforced for digging
in rose scented pot)
1.5.5. Extra-dimensional shift/EDR
The next discrimination was the extra-dimensional shift
(ED1) which assessed the ability to shift attentional set
which began with the introduction of a third set of novel
stimuli. The rat was reinforced for attending to a previously
irrelevant, variable dimension, e.g. digging medium. If the
animal had formed an attentional set, then they should
require signiﬁcantly more trials to achieve criterion perfor-
mance on ED1 than on ID1. After successful completion of
the ED1, the ﬁnal reversal of this session was  given (EDR1;
plastic beads)
1.5.6. Next day, learned irrelevance
After completing the EDR, the next day’s testing began
with an assessment of learned irrelevance that measured
the rat’s ability to ignore the dimension never paired with
reinforcement. This design allowed the experimenter to
maintain continuity in the complexity of the stimuli rather
than returning to stimuli that differed on only one dimen-
R.E. Cain et al. / Developmental Cognitive
Table  2
An overview of testing is provided and shows the age at which each series
of  test was  conducted. Drug administration began 30 min  prior to the ED
on days 3, 4 and 5. The order of drug doses was  counterbalanced across
subjects so that the order of drug administration was not confounded
by age. Additionally testing sequences were counterbalanced so that the
modality that was being reinforced on a given day was  not the same for
all  rats or for all doses of drug.
Day Testing sequence Age
1 Training to dig PND 39
2  Exemplar 1; exemplar 2; exemplar 3; SD PND 40
3 CD1; CDR; ID1; IDR1; ED1; EDR1 PND 41
4 LI1; CD2; CDR2; ID2; IDR2; ED2; EDR2 PND 42
5 LI2; CD3; CDR3; ID3; IDR3; ED3; EDR3 PND 43
sion, i.e. a SD. For this example, all pots were texturized but
the texture did not vary among stimulus pots. In the test of
learned irrelevance, changes are introduced in this dimen-
sion but all other aspects of the testing stimuli are the same
as the last reversal of the previous testing day.
After completion of this stage, testing was the same as
before beginning with a repetition of the previous order
of testing from the CD-EDR using novel stimuli. The third
day’s test began with a second test of learned irrelevance as
shown in Table 2. Each rat received every dose of atomox-
etine (0.0; 0.1 and 0.9 mg/kg/ml) with the order of doses
counterbalanced across subjects so that neither age nor
order of testing confounded the effects of dose. Similarly,
the sequences of testing were counterbalanced across all
subjects so that 1/3 of the subjects were ﬁrst reinforced
for attending to odor, 1/3 for attending to texture and
1/3 for attending to digging media. ED2 always required
rats to shift attention to the previously irrelevant, constant
dimension in the tests of CD1-EDR1. ED3 required rats to
shift attention to the dimension reinforced in the original
SD.
1.6. Injection procedures
In order to acclimate rats to injection procedures, each
rat was given a saline injection thirty minutes prior to the
onset of training to dig and the exemplar testing. On subse-
quent days, rats were given intra-peritoneal (i.p.) injections
of atomoxetine hydrochloride (Tocris Cookson, Ellisville,
MO)  thirty minutes prior to the onset of the ED in order
to test the hypothesis that it would improve the ability of
adolescent rats to shift attentional set. The order of doses
of atomoxetine, 0.0, 0.1, and 0.9 mg/kg/ml was counterbal-
anced across subjects.
1.7. Statistical analysis
All statistical analyses were performed with SPSS v. 17.0
(SPSS, Chicago, IL, USA). The number of trials required to
reach criterion performance and correct response latencies
were analyzed in separate ANOVA’s. Data from one ani-
mal  were excluded because he omitted responding after
all injections including placebo. The ﬁrst analysis assessed
the effects of atomoxetine on how well adolescent rats
formed and shifted attentional set using a repeated mea-
sures ANOVA of dose (3) × test (2). A series of planned
comparisons determined if there was a cost to shift atten- Neuroscience 1 (2011) 552– 559 555
tional set by comparing the number of trials to reach
criterion performance on the ED after vehicle injection to
those required to reach criterion on the ID. Additionally, the
effectiveness of atomoxetine in improving the performance
of adolescent rats on the EDs was  assessed by a series of
planned comparisons. The effects of atomoxetine on rever-
sals occurring after the EDs’ were analyzed using a repeated
measure ANOVA of dose (3). Additionally to conﬁrm that
the formation of an attentional set facilitated performance
the number of trials needed to reach criterion performance
on the IDs was compared to that needed on the CDs in
repeated measures ANOVA of test (2) × repetition (3). Per-
formance on reversal trials prior to the administration of
drug was compared using a repeated measures ANOVA
with the factors test (2) × day (3). Performance on LI1 and
LI2 was compared using a paired t-test.
2. Behavioral results
There was no difference in performance of discrimina-
tion based on the modality as the number of trials to reach
criterion was similar across all three tests performed dur-
ing exemplar training (F(2.20) = 2.75; p = 0.11). As a result,
this factor was  not included in subsequent analyses.
2.1. Effects of atomoxetine
2.1.1. The formation and shifting of attentional set
All rats required more trials to reach criterion perfor-
mance on the EDs than the IDs supporting the hypothesis
that there was a cognitive cost to shifting attentional set
(Test: F(1,10) = 6.37; p = 0.03; vehicle ID vs. ED: t(10) = 2.74;
p = 0.02). As shown in Fig. 1A, the lower dose, but not the
higher dose, of atomoxetine was  effective in reducing the
number of trials needed to reach criterion performance
during the ED (0.0 vs. 0.1 mg/kg/ml: t(10) = 2.44; p = 0.03;
0.0 vs. 0.9 mg/kg/ml; t(10) = 0.76; p = 0.47; test × dose:
F(2,20) = 3.87; p = 0.04; ε = 0.94). There was no main effect
of dose (F(2,20) = 1.97; p = 0.17). All subjects took longer
to make a correct response on the EDs than the IDs
(F(1,10) = 5.94; p = 0.04; Mean ± SEM; IDs: 3.69 ± 0.34 s;
EDs: 5.94 ± 0.83 s). There were no effects of atomoxetine
on correct response latencies (F(2,20) = 0.55; p = 0.55).
2.1.2. Reversal learning
There were no effects of atomoxetine on tests of reversal
learning in the analyses of trials needed to reach criterion
(Fig. 1B; F(2,20) = 0.42; p = 0.66) or correct response laten-
cies (F(2, 20) = 0.49; p = 0.62).
2.2. Pre-injection performance
2.2.1. Reversal learning
All rats required fewer trials to reach criterion per-
formance on the second reversal of the day when it
was compared to the ﬁrst reversal of the testing session
(F(1,10) = 13.49; p = 0.004; Mean ± SEM; REV 1: 25.3 ± 1.9;
REV 2: 15.3 ± 1.6) and took longer to emit correct responses
on the second reversal of the day when compared to
the ﬁrst (F(1,10) = 12.85; p = 0.005;Mean ± SEM; REV 1:
2.4 ± 0.2; REV 2: 4.1 ± 0.5 s). When the number of trials
556 R.E. Cain et al. / Developmental Cognitive
Fig. 1. (A) Subjects require fewer trials to reach criterion performance on
IDs’ (white bars) than EDs’ after the 0.0 mg/kg/ml dose (light gray bar)
and  the 0.9 mg/kg/ml dose (black bar). In contrast, performance on the
EDs after the 0.1 mg/kg/ml dose (dark gray bars) shows no cost of atten-
tional set shifting. Performance on the EDs after the 0.1 mg/kg/ml dose is
signiﬁcantly better than after either of the other doses.  Indicates that ED
performance is signiﬁcantly worse that ID at the same dose of drug. (B)
Previous work from our laboratory has shown that adolescents are less
able to perform reinforcement reversals than adults but neither dose of
atomoxetine facilitated this type of learning. Performance on this stage of
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prefrontal NE efﬂux is similar in adolescents and adultsesting depends upon the functional integrity of the orbitofrontal cortex
nd may be more reliant on serotonergic than noradrenergic function.
eeded to reach criterion on the ﬁrst reversal of the day
as compared to the second on subsequent testing days,
he effect was the same (all p > 0.66).
.2.2. Performance on compound discriminations
There was no difference in the number of trials to
each criterion performance when CD1, CD2 and CD3 were
ompared (F(2,20) = 0.26; p = 0.75; ε = 0.89). Moreover, rats
equired fewer trials to reach criterion performance on IDs
han CDs supporting the hypothesis that rats used an atten-
ional set to determine which stimulus attribute predicted
einforcement (F(2,20) = 21.76; p = 0.001). There were no
ifferences in response latencies between the ID and CD nor
ny differences in response latencies among CD1, CD2 and
D3 (all p > 0.64). There was a trend for improved perfor-
ance on tests of learned irrelevance with repeated testing
t(10) = 2.09; p > 0.06). Neuroscience 1 (2011) 552– 559
3.  Discussion
Adolescent rats’ ability to perform an attentional set
shift is facilitated by the administration of a low dose of
atomoxetine. The ability to perform shifts of attentional
set in adult rats has been shown to depend on optimal
levels of norepinephrine in the prelimbic cortex (Danet
et al., 2010; Lapiz et al., 2007; Lapiz and Morilak, 2006;
Milstein et al., 2007; Newman et al., 2008; Tait et al.,
2007). The lowest dose used in the present study was
selected because it has been shown to increase levels of
prefrontal NE without concurrent increases in other neu-
romodulators (Bymaster et al., 2002; Tzavara et al., 2007;
Wong et al., 1982). The higher dose used in the present
study was not effective in facilitating attentional set shift-
ing or reversal learning. This supports the hypothesis that
increased levels of NE produced by the lower dose of ato-
moxetine are sufﬁcient to improve executive function as
previously demonstrated (Newman et al., 2008). Though
higher levels of norepinephrine have been shown impair
cognition (Bouret and Sara, 2005; Arnsten, 2006a,b), the
higher dose used here did not impair cognition rather
it failed to improve it. Higher doses of atomoxetine, e.g.
0.9 mg/kg/ml produce less selective effects on NET and have
been shown to increase cortical NE, dopamine and acetyl-
choline (Bymaster et al., 2002; Tzavara et al., 2007). It is
unclear whether the lack of effect after the higher dose
results from concomitant release of other neuromodula-
tors counteracting the beneﬁcial increase in NE or is a result
of supraoptimal levels of this neuromodulator. Improve-
ments in cognitive function produced by atomoxetine are
hypothesized to depend upon binding at post-synaptic 2
receptors (Gamo et al., 2010). The present data and pre-
vious work (Murrin et al., 2007) support the hypothesis
these receptors exist in the adolescent brain in sufﬁcient
numbers to produce beneﬁcial effects.
Recent, unpublished data from our lab shows that rats
have a higher density of NET and lower density of DBH at
PND 40 than PND 60. These age-related differences have
been found in prelimbic, infralimbic and orbitofrontal cor-
tices. We hypothesize that this high density of NET in the
prefrontal cortices of adolescents decreases the amount
of NE available in adolescents to produce immaturities in
executive function. Increased cognitive ﬂexibility results
from higher levels of prefrontal NE (Aston-Jones and Cohen,
2005; Berridge and Waterhouse, 2003) as produced by
changes in the ﬁring of the locus coeruleus (Bouret and
Sara, 2005; Usher et al., 1999) or through the adminis-
tration of NE enhancing drugs (Arnsten, 2006a,b; Berridge
et al., 2006; Devilbiss and Berridge, 2008). High density
of NET in adolescent prefrontal cortex is hypothesized to
prevent increases in prefrontal NE and limit cognitive ﬂex-
ibility. NET blockade by atomoxetine prolongs the action of
NE in the synapse and is hypothesized to increase NE in the
prefrontal cortex of adolescent rats to allow attentional set
shifts.
Recent work by Finlay and colleagues has shown that(Boyce and Finlay, 2009). This may  seem in disagree-
ment with the present theoretical framework. One possible
explanation for this discrepancy may  lie in the fact that
ognitiveR.E. Cain et al. / Developmental C
these assessments were not made while rats were perform-
ing a cognitively demanding task and this type of cognitive
demand may  be necessary to reveal lower levels of NE in
adolescent rats. In other words, though adolescent rats may
show similar levels of NE during conditions of low cognitive
demand, they may  be unable to sustain release in situations
that require high levels of cognitive ﬂexibility. Neuromod-
ulator levels in prefrontal cortex substantially increase
during conditions of high cognitive demand (Dalley et al.,
2001; Himmelheber et al., 1997, 2000, 2001; McGaughy
et al., 2002). Rats with pre-existing damage to neuromod-
ulatory systems may  show normal efﬂux when cognitive
demand is low but are unable to maintain neuromodula-
tory levels when assessments are made during conditions
of high demand (McGaughy et al., 2002; Parikh et al., 2007).
We hypothesize that adolescent rats would show lower
levels of cortical NE during attentional testing than adults,
but additional studies are required to address this question.
Systemic administration of atomoxetine did not
improve reversal learning in adolescent rats. This seems
unlikely to be due to a ceiling effect as adolescent rats
have previously been shown to be less proﬁcient at rever-
sal learning than adults (Newman and McGaughy, 2011).
In humans, adolescents with behavioral disorders (Ernst
et al., 2003; Romer et al., 2009), mood disorders (Dickstein
et al., 2009) and psychopathic traits (Finger et al., 2008)
show an inability to modify responding based on changes
in reinforcement contingencies so understanding this form
of executive function in adolescents is likely to have wide-
ranging implications. One explanation for the lack of effect
of atomoxetine on reversal learning is that it is more depen-
dent upon serotonin (Clarke et al., 2004, 2005; Lapiz-Bluhm
et al., 2009; Murphy et al., 2002) and dopamine (Cools
et al., 2001a,b, 2004; Dalley et al., 2004; Takahashi et al.,
2009) than norepinephrine. Maturation of serotonergic
systems has been shown to precede that of noradrener-
gic systems in rats (Murrin et al., 2007), humans (Verney,
1999) and non-human primates (Lambe et al., 2000). Based
on these ﬁndings, adolescents should be expected to be
proﬁcient at reversal learning sooner than attentional set
shifting. However, recent data do not support this hypothe-
sis. Adolescent rats could successfully perform attentional
set shifts at a younger age than reversals (Newman and
McGaughy, 2011). One theoretical framework suggests
that NE is critical to learning in situations of unexpected,
but not expected, uncertainty (Yu and Dayan, 2005). This
framework suggests that the cognitive demands of the
ﬁrst reversal encountered maydepend upon NE, but sub-
sequent reversal learning may  be more dependent upon
other neuromodulators. Unpublished data from our labo-
ratory suggests that noradrenergic deafferentation of the
orbitofrontal cortex in adult rats produces deﬁcits in the
ﬁrst test of reversal learning (CDR), but not subsequent
tests of reversals. In the present study the effects of ato-
moxetine were tested not on the ﬁrst reversal but the
third which may  be less dependent upon NE. It is unclear
whether the administration of atomoxetine would improve
performance on the test of the ﬁrst reversal but future stud-
ies should explore this possibility.
Behavioral studies have shown that the attentional per-
formance of adolescent rats is qualitatively similar to that Neuroscience 1 (2011) 552– 559 557
of adult rats after noradrenergic lesions (McGaughy et al.,
2008; Newman et al., 2008; Tait et al., 2007). The fact
that performance in both groups is improved by doses of
a selective norepinephrine reuptake blocker suggest that
adolescents have functional deﬁcits in prefrontal nora-
drenergic systems similar to that produced by selective
deafferentation. Studies have shown that juvenile rats have
higher densities of NET in the frontal cortex than adults
(Moll et al., 2000; Sanders et al., 2005). These studies
assessed frontal cortex NET density as a whole without
regard for functionally distinct subregions and did not
assess NET density in adolescents. We  have recently found
that NET density is higher at PND 40 than PND 60 in pre-
limbic and orbitofrontal cortices (Agster et al., unpublished
data). We  have also found that dopamine beta hydroxylase
levels in the same prefrontal subregions assessed at the
same ages are lower. Together both the lower levels of syn-
thetic enzyme and higher NET are hypothesized to produce
a functional NE deﬁcit in the prefrontal cortices of adoles-
cents. At present, it is unclear whether strategies aimed
at increasing this synthetic precursor would also produce
more ﬂexible attentional performance. Finally, it is impor-
tant to remember that while the present study supports
the hypothesis that adolescent attention differs from adult
because of higher densities of prefrontal NET more stud-
ies are required to understand how chronic NET blockade
may  impact the development of executive function and its
biological substrates.
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